Risk factors for heart failure

Medical Clinics of North America

Volumn 88, Issue 5, 2004, Pages 1145-1172

  Kenchaiah, Satish ^a,b   Narula, Jagat ^c   Vasan, Ramachandran S ^a,b,d  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d The National Heart   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN C;

ALCOHOL CONSUMPTION; BREATHING; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ETHNOLOGY; GENETIC VARIABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LUNG FUNCTION; MENTAL STRESS; MULTIVARIATE ANALYSIS; OBESITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; SLEEP DISORDER; VALVULAR HEART DISEASE;

AGE DISTRIBUTION; ALCOHOLISM; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; EPIDEMIOLOGIC STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HEART VALVE DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OBESITY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SLEEP APNEA SYNDROMES; SMOKING;

EID: 4444320145     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.04.016     Document Type: Review

References (222)

1. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 347:2002;1397-1402
2. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 285:1971;1441-1446
3. Remes J., Reunanen A., Aromaa A., Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 13:1992;588-593
4. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 22:1993;6A-13A
5. Kimmelstiel C.D., Konstam M.A. Heart failure in women. Cardiology. 86:1995;304-309
6. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 98:1998;2282-2289
7. Chae C.U., Pfeffer M.A., Glynn R.J., Mitchell G.F., Taylor J.O., Hennekens C.H. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 281:1999;634-639
8. Chen Y.T., Vaccarino V., Williams C.S., Butler J., Berkman L.F., Krumholz H.M. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med. 106:1999;605-612
9. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 35:2000;1628-1637
10. Abramson J., Berger A., Krumholz H.M., Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 161:2001;1725-1730
11. Abramson J.L., Williams S.A., Krumholz H.M., Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 285:2001;1971-1977
12. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., Whelton P.K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 161:2001;996-1002
13. Wilhelmsen L., Rosengren A., Eriksson H., Lappas G. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med. 249:2001;253-261
14. Lloyd-Jones D.M., Larson M.G., Leip E.P., Beiser A., D'Agostino R.B., Kannel W.B., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 106:2002;3068-3072
15. Dunlap S.H., Sueta C.A., Tomasko L., Adams K.F. Jr. Association of body mass, gender and race with heart failure primarily due to hypertension. J Am Coll Cardiol. 34:1999;1602-1608
16. Kannel W.B., Castelli W.P., McNamara P.M., McKee P.A., Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 287:1972;781-787
17. Eriksson H., Svardsudd K., Larsson B., Ohlson L.O., Tibblin G., Welin L., et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J. 10:1989;647-656
18. Levy D., Larson M.G., Vasan R.S., Kannel W.B., Ho K.K. The progression from hypertension to congestive heart failure. JAMA. 275:1996;1557-1562
19. Vaccarino V., Holford T.R., Krumholz H.M. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol. 36:2000;130-138
20. Haider A.W., Larson M.G., Franklin S.S., Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 138:2003;10-16
21. Frohlich E.D., Apstein C., Chobanian A.V., Devereux R.B., Dustan H.P., Dzau V., et al. The heart in hypertension. N Engl J Med. 327:1992;998-1008
22. Vasan R.S., Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 156:1996;1789-1796
23. Frohlich E.D. State of the art lecture. Risk mechanisms in hypertensive heart disease. Hypertension. 34:1999;782-789
24. Kenchaiah S., Pfeffer M.A. Cardiac remodeling in systemic hypertension. Med Clin N Am. 88:2004;115-130
25. Moser M., Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 27:1996;1214-1218
26. Kostis J.B., Davis B.R., Cutler J., Grimm R.H. Jr., Berge K.G., Cohen J.D., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 278:1997;212-216
27. Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 277:1997;739-745
28. Davis B.R., Cutler J.A., Furberg C.D., Wright J.T., Farber M.A., Felicetta J.V., et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med. 137:2002;313-320
29. Kannel W.B., Levy D., Cupples L.A. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol. 10:(Suppl 6):1987;S135-S140
30. Marcus M.L., Harrison D.G., Chilian W.M., Koyanagi S., Inou T., Tomanek R.J., et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation. 75:1987;I19-I25
31. Dellsperger K.C., Marcus M.L. Effects of left ventricular hypertrophy on the coronary circulation. Am J Cardiol. 65:1990;1504-1510
32. Polese A., De Cesare N., Montorsi P., Fabbiocchi F., Guazzi M., Loaldi A., et al. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 83:1991;845-853
33. Beache G.M., Herzka D.A., Boxerman J.L., Post W.S., Gupta S.N., Faranesh A.Z., et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation. 104:2001;1214-1217
34. Kannel W.B., Gordon T., Castelli W.P., Margolis J.R. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 72:1970;813-822
35. Kannel W.B., D'Agostino R.B., Silbershatz H., Belanger A.J., Wilson P.W., Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 159:1999;1197-1204
36. van Hoeven K.H., Factor S.M. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 82:1990;848-855
37. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81:1990;1161-1172
38. Pfeffer M.A. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med. 46:1995;455-466
39. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 327:1992;685-691
40. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J. Jr., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 327:1992;669-677
41. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 332:1995;80-85
42. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 3:1997;249-254
43. Aronow W.S., Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 90:2002;147-149
44. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 34:1974;29-34
45. Shindler D.M., Kostis J.B., Yusuf S., Quinones M.A., Pitt B., Stewart D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 77:1996;1017-1020
46. Bonow R.O., Mitch W.E., Nesto R.W., O'Gara P.T., Becker R.C., Clark L.T., et al. Prevention conference VI: diabetes and cardiovascular disease: writing group V: management of cardiovascular-renal complications. Circulation. 105:2002;e159-e164
47. Solomon S.D., St. John S.M., Lamas G.A., Plappert T., Rouleau J.L., Skali H., et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 106:2002;1251-1255
48. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 321:2000;405-412
49. Iribarren C., Karter A.J., Go A.S., Ferrara A., Liu J.Y., Sidney S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 103:2001;2668-2673
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853
51. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 108:2003;2941-2948
52. Johansson S., Wallander M.A., Ruigomez A., Garcia Rodriguez L.A. Incidence of newly diagnosed heart failure in UK general practice. Eur J Heart Fail. 3:2001;225-231
53. Carabello B.A., Crawford F.A. Jr. Valvular heart disease. N Engl J Med. 337:1997;32-41
54. Bonow R.O., Carabello B., de Leon A.C. Jr., Edmunds L.H. Jr., Fedderly B.J., Freed M.D., et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 98:1998;1949-1984
55. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med. 347:2002;305-313
56. Urbano-Marquez A., Estruch R., Navarro-Lopez F., Grau J.M., Mont L., Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 320:1989;409-415
57. Rubin E., Urbano-Marquez A. Alcoholic cardiomyopathy. Alcohol Clin Exp Res. 18:1994;111-114
58. Klatsky A.L., Friedman G.D., Siegelaub A.B., Gerard M.J. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med. 296:1977;1194-1200
59. Jackson R., Stewart A., Beaglehole R., Scragg R. Alcohol consumption and blood pressure. Am J Epidemiol. 122:1985;1037-1044
60. Marmot M.G., Elliott P., Shipley M.J., Dyer A.R., Ueshima H., Beevers D.G., et al. Alcohol and blood pressure: the INTERSALT study. BMJ. 308:1994;1263-1267
61. Gillman M.W., Cook N.R., Evans D.A., Rosner B., Hennekens C.H. Relationship of alcohol intake with blood pressure in young adults. Hypertension. 25:1995;1106-1110
62. Lee W.K., Regan T.J. Alcoholic cardiomyopathy: is it dose-dependent? Congest Heart Fail. 8:2002;303-306
63. Walsh C.R., Larson M.G., Evans J.C., Djousse L., Ellison R.C., Vasan R.S., et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 136:2002;181-191
64. Ajani U.A., Hennekens C.H., Spelsberg A., Manson J.E. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med. 160:2000;1025-1030
65. Gaziano J.M., Buring J.E., Breslow J.L., Goldhaber S.Z., Rosner B., VanDenburgh M., et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 329:1993;1829-1834
66. Camargo C.A. Jr., Stampfer M.J., Glynn R.J., Grodstein F., Gaziano J.M., Manson J.E., et al. Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in US male physicians. Ann Intern Med. 126:1997;372-375
67. Rubin R. Effect of ethanol on platelet function. Alcohol Clin Exp Res. 23:1999;1114-1118
68. Ridker P.M., Vaughan D.E., Stampfer M.J., Glynn R.J., Hennekens C.H. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA. 272:1994;929-933
69. Facchini F.S., Hollenbeck C.B., Jeppesen J., Chen Y.D., Reaven G.M. Insulin resistance and cigarette smoking. Lancet. 339:1992;1128-1130
70. Feskens E.J., Kromhout D. Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle-aged men. The Zutphen Study. Am J Epidemiol. 130:1989;1101-1108
71. Rimm E.B., Manson J.E., Stampfer M.J., Colditz G.A., Willett W.C., Rosner B., et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health. 83:1993;211-214
72. Rimm E.B., Chan J., Stampfer M.J., Colditz G.A., Willett W.C. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ. 310:1995;555-559
73. Uchimoto S., Tsumura K., Hayashi T., Suematsu C., Endo G., Fujii S., et al. Impact of cigarette smoking on the incidence of type 2 diabetes mellitus in middle-aged Japanese men: the Osaka Health Survey. Diabet Med. 16:1999;951-955
74. Manson J.E., Ajani U.A., Liu S., Nathan D.M., Hennekens C.H. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med. 109:2000;538-542
75. Michael P.R. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 81:2000;219-230
76. Burke A., Fitzgerald G.A. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis. 46:2003;79-90
77. Gvozdjakova A., Kucharska J., Gvozdjak J. Effect of smoking on the oxidative processes of cardiomyocytes. Cardiology. 81:1992;81-84
78. Gvozdjak J., Gvozdjakova A., Kucharska J., Bada V., Kovalikova V., Zachar A. Metabolic disorders of cardiac muscle in alcoholic and smoke cardiomyopathy. Cor Vasa. 31:1989;312-320
79. Kannel W.B., Ho K., Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 72:1994;S3-S9
80. Schillaci G., Vaudo G., Reboldi G., Verdecchia P., Lupattelli G., Pasqualini L., et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens. 19:2001;2265-2270
81. Horio T., Miyazato J., Kamide K., Takiuchi S., Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 16:2003;938-944
82. Jullien V., Gosse P., Ansoborlo P., Lemetayer P., Clementy J. Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive. J Hypertens. 16:1998;1043-1047
83. Chae C.U., Albert C.M., Glynn R.J., Guralnik J.M., Curhan G.C. Mild renal insufficiency and risk of congestive heart failure in men and women > or = 70 years of age. Am J Cardiol. 92:2003;682-686
84. Fried L.F., Shlipak M.G., Crump C., Bleyer A.J., Gottdiener J.S., Kronmal R.A., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 41:2003;1364-1372
85. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 35:2000;681-689
86. Mourad J.J., Girerd X., Boutouyrie P., Laurent S., Safar M., London G. Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension. 30:1997;1425-1430
87. Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 102:2000;203-210
88. Shlipak M.G., Fried L.F., Crump C., Bleyer A.J., Manolio T.A., Tracy R.P., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 107:2003;87-92
89. Herbelin A., Urena P., Nguyen A.T., Zingraff J., Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 39:1991;954-960
90. Descamps-Latscha B., Herbelin A., Nguyen A.T., Roux-Lombard P., Zingraff J., Moynot A., et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 154:1995;882-892
91. Bostom A.G., Culleton B.F. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol. 10:1999;891-900
92. Vasan R.S., Beiser A., D'Agostino R.B., Levy D., Selhub J., Jacques P.F., et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 289:2003;1251-1257
93. Vasan R.S., Sullivan L.M., Roubenoff R., Dinarello C.A., Harris T., Benjamin E.J., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 107:2003;1486-1491
94. Chaudhary B.A., Ferguson D.S., Speir W.A. Jr. Pulmonary edema as a presenting feature of sleep apnea syndrome. Chest. 82:1982;122-124
95. Fletcher E.C., Proctor M., Yu J., Zhang J., Guardiola J.J., Hornung C., et al. Pulmonary edema develops after recurrent obstructive apneas. Am J Respir Crit Care Med. 160:1999;1688-1696
96. Shahar E., Whitney C.W., Redline S., Lee E.T., Newman A.B., Javier N.F., et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 163:2001;19-25
97. Bradley T.D., Floras J.S. Sleep apnea and heart failure: part I: obstructive sleep apnea. Circulation. 107:2003;1671-1678
98. Mcevoy R.D. Obstructive sleep apnea and heart failure: two unhappy bedfellows. Am J Respir Crit Care Med. 169:2004;329-331
99. Hedner J.A., Wilcox I., Laks L., Grunstein R.R., Sullivan C.E. A specific and potent pressor effect of hypoxia in patients with sleep apnea. Am Rev Respir Dis. 146:1992;1240-1245
100. Sajkov D., Wang T., Saunders N.A., Bune A.J., Mcevoy R.D. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 165:2002;152-158
101. Peppard P.E., Young T., Palta M., Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 342:2000;1378-1384
102. Kaneko Y., Floras J.S., Usui K., Plante J., Tkacova R., Kubo T., et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 348:2003;1233-1241
103. Mansfield D.R., Gollogly N.C., Kaye D.M., Richardson M., Bergin P., Naughton M.T. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med. 169:2004;361-366
104. Kokkinos P.F., Narayan P., Colleran J.A., Pittaras A., Notargiacomo A., Reda D., et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med. 333:1995;1462-1467
105. Wannamethee S.G., Shaper A.G., Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet. 351:1998;1603-1608
106. Hu F.B., Sigal R.J., Rich-Edwards J.W., Colditz G.A., Solomon C.G., Willett W.C., et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA. 282:1999;1433-1439
107. Manson J.E., Hu F.B., Rich-Edwards J.W., Colditz G.A., Stampfer M.J., Willett W.C., et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 341:1999;650-658
108. Hypertension Detection and Follow-up Program Cooperative Group. Educational level and 5-year all-cause mortality in the Hypertension Detection and Follow-up Program. Hypertension. 9:1987;641-646
109. Chaturvedi N., Stephenson J.M., Fuller J.H. The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care. 19:1996;423-430
110. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., Whelton P.K. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first National Health and Nutrition Examination Survey epidemiologic follow-up study. Arch Intern Med. 162:2002;1619-1624
111. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 10:1997;49S-55S
112. Luft F.C., Weinberger M.H. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am J Clin Nutr. 65:1997;612S-617S
113. Reisin E. Sodium and obesity in the pathogenesis of hypertension. Am J Hypertens. 3:1990;164-167
114. Andreoli T.E. Pathogenesis of renal sodium retention in congestive heart failure. Miner Electrolyte Metab. 25:1999;11-20
115. Sugimoto K., Fujimura A., Takasaki I., Tokita Y., Iwamoto T., Takizawa T., et al. Effects of renin-angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats. Hypertens Res. 21:1998;163-168
116. Messerli F.H., Schmieder R.E., Weir M.R. Salt. A perpetrator of hypertensive target organ disease? Arch Intern Med. 157:1997;2449-2452
117. Kupari M., Koskinen P., Virolainen J. Correlates of left ventricular mass in a population sample aged 36 to 37 years. Focus on lifestyle and salt intake. Circulation. 89:1994;1041-1050
118. Frohlich E.D., Chien Y., Sesoko S., Pegram B.L. Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol. 264:1993;R30-R34
119. Liebson P.R., Grandits G., Prineas R., Dianzumba S., Flack J.M., Cutler J.A., et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 87:1993;476-486
120. Schmieder R.E., Messerli F.H., Garavaglia G.E., Nunez B.D. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation. 78:1988;951-956
121. Langenfeld M.R., Schobel H., Veelken R., Weihprecht H., Schmieder R.E. Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. Eur Heart J. 19:1998;951-958
122. Kannel W.B. Vital epidemiologic clues in heart failure. J Clin Epidemiol. 53:2000;229-235
123. Kannel W.B., Seidman J.M., Fercho W., Castelli W.P. Vital capacity and congestive heart failure. The Framingham study. Circulation. 49:1974;1160-1166
124. Marcus E.B., Curb J.D., MacLean C.J., Reed D.M., Yano K. Pulmonary function as a predictor of coronary heart disease. Am J Epidemiol. 129:1989;97-104
125. Enright P.L., Kronmal R.A., Smith V.E., Gardin J.M., Schenker M.B., Manolio T.A. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study. Chest. 107:1995;28-35
126. Perlman L.V., Ferguson S., Bergum K., Isenberg E.L., Hammarsten J.F. Precipitation of congestive heart failure: social and emotional factors. Ann Intern Med. 75:1971;1-7
127. Williams S.A., Kasl S.V., Heiat A., Abramson J.L., Krumholz H.M., Vaccarino V. Depression and risk of heart failure among the elderly: a prospective community-based study. Psychosom Med. 64:2002;6-12
128. Roy A., Pickar D., De Jong J., Karoum F., Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry. 45:1988;849-857
129. Veith R.C., Lewis N., Linares O.A., Barnes R.F., Raskind M.A., Villacres E.C., et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 51:1994;411-422
130. Tavazzi L., Zotti A.M., Mazzuero G. Acute pulmonary edema provoked by psychologic stress. Report of two cases. Cardiology. 74:1987;229-235
131. Rozanski A., Bairey C.N., Krantz D.S., Friedman J., Resser K.J., Morell M., et al. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med. 318:1988;1005-1012
132. Giannuzzi P., Shabetai R., Imparato A., Temporelli P.L., Bhargava V., Cremo R., et al. Effects of mental exercise in patients with dilated cardiomyopathy and congestive heart failure. An echocardiographic Doppler study. Circulation. 83:1991;II155-II165
133. Pasic J., Levy W.C., Sullivan M.D. Cytokines in depression and heart failure. Psychosom Med. 65:2003;181-193
134. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 160:2000;2101-2107
135. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 336:1997;1350-1355
136. Gaudron P., Eilles C., Ertl G., Kochsiek K. Compensatory and noncompensatory left ventricular dilatation after myocardial infarction: time course and hemodynamic consequences at rest and during exercise. Am Heart J. 123:1992;377-385
137. Jacob R., Gulch R.W. Functional significance of ventricular dilatation. Reconsideration of Linzbach's concept of chronic heart failure. Basic Res Cardiol. 83:1988;461-475
138. Ross J. Jr. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis. 18:1976;255-264
139. Aurigemma G.P., Gottdiener J.S., Shemanski L., Gardin J., Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 37:2001;1042-1048
140. Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 108:2003;977-982
141. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 100:1999;999-1008
142. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 35:2000;569-582
143. St. John S.M., Pfeffer M.A., Plappert T., Rouleau J.L., Moye L.A., Dagenais G.R., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 89:1994;68-75
144. Greenberg B., Quinones M.A., Koilpillai C., Limacher M., Shindler D., Benedict C., et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 91:1995;2573-2581
145. Clements I.P., Davis B.J., Wiseman G.A. Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation. Nucl Med Commun. 23:2002;521-527
146. Lee B.H., Goodenday L.S., Muswick G.J., Yasnoff W.A., Leighton R.F., Skeel R.T. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 9:1987;184-188
147. Nousiainen T., Vanninen E., Jantunen E., Puustinen J., Remes J., Rantala A., et al. Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: a prospective radionuclide ventriculographic and echocardiographic study. Leuk Lymphoma. 43:2002;1807-1811
148. Von Hoff D.D., Layard M.W., Basa P., Davis H.L. Jr., Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91:1979;710-717
149. Green D.M., Grigoriev Y.A., Nan B., Takashima J.R., Norkool P.A., D'Angio G.J., et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol. 19:2001;1926-1934
150. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 97:2003;2869-2879
151. Gottlieb S.L., Edmiston W.A. Jr., Haywood L.J. Late, late doxorubicin cardiotoxicity. Chest. 78:1980;880-882
152. Heerdink E.R., Leufkens H.G., Herings R.M., Ottervanger J.P., Stricker B.H., Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 158:1998;1108-1112
153. Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 160:2000;777-784
154. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 286:2001;421-426
155. Stehouwer C.D., Nauta J.J., Zeldenrust G.C., Hackeng W.H., Donker A.J., den Ottolander G.J. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 340:1992;319-323
156. Haffner S.M., Gonzales C., Valdez R.A., Mykkanen L., Hazuda H.P., Mitchell B.D., et al. Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia. 36:1993;1002-1006
157. Mykkanen L., Haffner S.M., Kuusisto J., Pyorala K., Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes. 43:1994;552-557
158. Niskanen L., Turpeinen A., Penttila I., Uusitupa M.I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 21:1998;1861-1869
159. Giaconi S., Levanti C., Fommei E., Innocenti F., Seghieri G., Palla L., et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens. 2:1989;259-261
160. Agrawal B., Berger A., Wolf K., Luft F.C. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 14:1996;223-228
161. Pedrinelli R., Dell'Omo G., Penno G., Bandinelli S., Bertani A., Di Bello V., et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension. 35:2000;48-54
162. Dell'Omo G., Giorgi D., Di Bello V., Mariani M., Pedrinelli R. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med. 254:2003;76-84
163. Shulman N.B., Ford C.E., Hall W.D., Blaufox M.D., Simon D., Langford H.G., et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 13:1989;I80-I193
164. Forsblom C.M., Groop P.H., Ekstrand A., Totterman K.J., Sane T., Saloranta C., et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care. 21:1998;1932-1938
165. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1997;1286-1292
166. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 27:1996;517-527
167. Chen P., Poddar R., Tipa E.V., Dibello P.M., Moravec C.D., Robinson K., et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul. 39:1999;93-109
168. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98:1996;5-7
169. Blacher J., Demuth K., Guerin A.P., Vadez C., Moatti N., Safar M.E., et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol. 12:1999;248-255
170. Miller A., Mujumdar V., Palmer L., Bower J.D., Tyagi S.C. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens. 15:2002;157-163
171. Chilian W.M. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation. 95:1997;522-528
172. Lentz S.R. Homocysteine and vascular dysfunction. Life Sci. 61:1997;1205-1215
173. Symons J.D., Mullick A.E., Ensunsa J.L., Ma A.A., Rutledge J.C. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol. 22:2002;772-780
174. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 338:1998;1042-1050
175. Chao C.L., Tsai H.H., Lee C.M., Hsu S.M., Kao J.T., Chien K.L., et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 147:1999;379-386
176. Whincup P.H., Refsum H., Perry I.J., Morris R., Walker M., Lennon L., et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart. 82:1999;448-454
177. Vasan R.S., Sullivan L.M., D'Agostino R.B., Roubenoff R., Harris T., Sawyer D.B., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 139:2003;642-648
178. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res. 30:1995;825-834
179. Ren J., Samson W.K., Sowers J.R. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol. 31:1999;2049-2061
180. Leri A., Liu Y., Wang X., Kajstura J., Malhotra A., Meggs L.G., et al. Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. Circ Res. 84:1999;752-762
181. Welch S., Plank D., Witt S., Glascock B., Schaefer E., Chimenti S., et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res. 90:2002;641-648
182. Wang L., Ma W., Markovich R., Chen J.W., Wang P.H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 83:1998;516-522
183. Donath M.Y., Zapf J., Eppenberger-Eberhardt M., Froesch E.R., Eppenberger H.M. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc Natl Acad Sci USA. 91:1994;1686-1690
184. Duerr R.L., Huang S., Miraliakbar H.R., Clark R., Chien K.R., Ross J. Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 95:1995;619-627
185. Reiss K., Cheng W., Ferber A., Kajstura J., Li P., Li B., et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci USA. 93:1996;8630-8635
186. Buerke M., Murohara T., Skurk C., Nuss C., Tomaselli K., Lefer A.M. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA. 92:1995;8031-8035
187. Serneri G.G., Modesti P.A., Boddi M., Cecioni I., Paniccia R., Coppo M., et al. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res. 85:1999;57-67
188. Ambler G.R., Johnston B.M., Maxwell L., Gavin J.B., Gluckman P.D. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I. Cardiovasc Res. 27:1993;1368-1373
189. Vecchione C., Colella S., Fratta L., Gentile M.T., Selvetella G., Frati G., et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension. 37:2001;1480-1485
190. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol. 274:1998;R577-R595
191. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753-6757
192. Schulz R., Nava E., Moncada S. Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 105:1992;575-580
193. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312
194. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389
195. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241
196. Dutka D.P., Elborn J.S., Delamere F., Shale D.J., Morris G.K. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 70:1993;141-143
197. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566
198. Wiedermann C.J., Beimpold H., Herold M., Knapp E., Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol. 22:1993;1897-1901
199. Munger M.A., Johnson B., Amber I.J., Callahan K.S., Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 77:1996;723-727
200. Raymond R.J., Dehmer G.J., Theoharides T.C., Deliargyris E.N. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J. 141:2001;435-438
201. Baumgarten G., Knuefermann P., Mann D.L. Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc Med. 10:2000;216-223
202. Hirota H., Yoshida K., Kishimoto T., Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 92:1995;4862-4866
203. Mann D.L. Interleukin-6 and viral myocarditis: the yin-yang of cardiac innate immune responses. J Mol Cell Cardiol. 33:2001;1551-1553
204. Wollert K.C., Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 6:2001;95-103
205. Tracy R.P., Lemaitre R.N., Psaty B.M., Ives D.G., Evans R.W., Cushman M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 17:1997;1121-1127
206. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979
207. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 105:2002;1890-1896
208. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 350:2004;655-663
209. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med. 339:1998;321-328
210. Brunner F., Wolkart G. Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res. 51:2001;577-584
211. Kohno M., Yokokawa K., Yasunari K., Kano H., Minami M., Ueda M., et al. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ Res. 81:1997;585-590
212. Herring N., Zaman J.A., Paterson D.J. Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway. Am J Physiol Heart Circ Physiol. 281:2001;H2318-H2327
213. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:1998;9-13
214. Schirmer H., Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso Study. Eur Heart J. 20:1999;755-763
215. Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 288:2002;1252-1259
216. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 347:2002;1135-1142
217. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 10:2004;248-254
218. Saeed M.M., Saboohi K., Osman A.S., Bokhari A.M., Frossard P.M. Association of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with essential hypertension. J Hum Hypertens. 17:2003;719-723
219. Gilfix B.M. Hyperhomocysteinemia: genetic determinants and selected mouse models. Clin Invest Med. 26:2003;121-132
220. Benetos A., Gautier S., Ricard S., Topouchian J., Asmar R., Poirier O., et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation. 94:1996;698-703
221. Baliga R.R., Narula J. Pharmacogenomics of congestive heart failure. Med Clin N Am. 87:2003;569-578. xiv
222. Rea T.D., Psaty B.M., Heckbert S.R., Cushman M., Meilahn E., Olson J.L., et al. Hormone replacement therapy and the risk of incident congestive heart failure: the Cardiovascular Health Study. J Womens Health (Larchmt). 12:2003;341-350